European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976—1996

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 • 1,494 citations

Prognostic factors in cancer

2003 • 285 citations

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients

1995 • 276 citations

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)

1993 • 259 citations

MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS

1995 • 234 citations

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

1993 • 208 citations

Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1997 • 206 citations

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological Group

1986 • 204 citations

Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer Trials

1989 • 111 citations

The Final Analysis of the EORTC Genito-Urinary T ract Cancer Co-Operative Group Phase III Clinical Trial (Protocol 30805) Comparing Orchidectomy, Orchidectomy plus Cyproterone Acetate and Low Dose Stilboestrol in the Management of Metastatic Carcinoma of the Prostate

1995 • 104 citations

A Comparison of the Effect of Diethylstilbestrol with Low Dose Estramustine Phosphate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Phase III Trial of the European Organization for Research on Treatment of Cancer

1986 • 79 citations

Controlled Clinical Trials in Urologic Oncology

1983 • 69 citations

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

1996 • 49 citations

Prognostic Factors in Cancer

1996 • 47 citations

The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials

1998 • 45 citations

Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer

1998 • 39 citations

Antiandrogens in the Treatment of Prostatic Cancer

1979 • 37 citations

New Hormonal Therapy in Prostate Cancer: Combined Use of a Pure Antiandrogen and an LHRH Agonist

1983 • 35 citations

Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)

1993 • 30 citations

Treatment response criteria for prostatic cancer

1984 • 30 citations

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group

1995 • 30 citations

Combined androgen blockade

1989 • 22 citations

Liarozole (R75251) in hormone-resistant prostate cancer patients

1997 • 16 citations

EORTC Phase II chemotherapy studies in prostate cancer.

1985 • 7 citations

Design and analysis of prostate cancer trials.

1994 • 2 citations

Hormone-Independent Prostate Cancer: Management of the Disease Continuum

1994 • 2 citations